Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: Between 2013 and 2016, 65 patients were assigned to a treatment group (33 in the GEMOX-T arm, 32 in the GT arm). The ORR was 18.2% [95% confidence interval (CI), 8.82-27.58] in the GEMOX-T arm and 6.2% (95% CI, 0.34-12.06) in the GT arm (p=0.051). The disease control rate was significantly superior in the GEMOX-T arm compared to the GT arm (72.7% vs. 43.8%, p=0.019). After a median follow-up of 19.7 months, the median progression-free survival (PFS) was 3.9 months for the GEMOX-T arm and 1.4 months for the GT arm (p=0.033). However, this did not translate to an improvement in overall survival. The most common grade 3 or higher hematologic adverse events were neutropenia (16.9%) and anemia (13.8%). CONCLUSION:
|
Authors | Sung Hee Lim, Jina Yun, Min Young Lee, Han Jo Kim, Kyoung Ha Kim, Se Hyung Kim, Sang Chul Lee, Sang Byung Bae, Chan Kyu Kim, Namsu Lee, Kyu Taek Lee, Seong Kyu Park, Yun Nah Lee, Jong Ho Moon |
Journal | Yonsei medical journal
(Yonsei Med J)
Vol. 62
Issue 8
Pg. 671-678
(Aug 2021)
ISSN: 1976-2437 [Electronic] Korea (South) |
PMID | 34296544
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Copyright | © Copyright: Yonsei University College of Medicine 2021. |
Chemical References |
- Oxaliplatin
- Deoxycytidine
- Erlotinib Hydrochloride
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Deoxycytidine
(analogs & derivatives)
- Erlotinib Hydrochloride
(adverse effects)
- Humans
- Oxaliplatin
(therapeutic use)
- Pancreatic Neoplasms
(drug therapy)
- Treatment Outcome
- Gemcitabine
|